Differential effects of glyoxalase 1 overexpression on diabetic atherosclerosis and renal dysfunction in streptozotocin-treated, apolipoprotein E-deficient mice

Physiological Reports

Volumn 2, Issue 6, 2014, Pages

  Geoffrion, Michèle ^a   Du, Xueliang ^b   Irshad, Zehra ^c   Vanderhyden, Barbara C ^d   Courville, Kerri ^d   Sui, Guangzhi ^b   D’Agati, Vivette D ^e   Ott Braschi, Sylvie ^a   Rabbani, Naila ^c   Thornalley, Paul J ^c   Brownlee, Michael ^b   Milne, Ross W ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF WARWICK   (United Kingdom)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^e Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

ApoE deficient mice; Atherosclerosis; Diabetes; Glyoxalase; Nephropathy

Indexed keywords

1,2 DICARBONYL DERIVATIVE; CHOLESTEROL; GLUTATHIONE; GLYOXAL; HYDROXYACYLGLUTATHIONE HYDROLASE; LACTOYLGLUTATHIONE LYASE; METHYLGLYOXAL; TRIACYLGLYCEROL;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; BIOACCUMULATION; BODY WEIGHT; CONTROLLED STUDY; DISEASE SEVERITY; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC MANIPULATION; HISTOPATHOLOGY; HYPERLIPOPROTEINEMIA TYPE 3; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LIPID STORAGE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN MICROARRAY; SEVERE RENAL IMPAIRMENT; TANDEM MASS SPECTROMETRY; WESTERN BLOTTING;

EID: 85003530455     PISSN: None     EISSN: 2051817X     Source Type: Journal    
DOI: 10.14814/phy2.12043     Document Type: Article

References (90)

1. Ahmed, N., and P. J. Thornalley. 2007. Advanced glycation endproducts: what is their relevance to diabetic complications. Diabetes Obes. Metab. 9:233-245.
2. Ahmed, N., O. K. Argirov, H. S. Minhas, C. A. A. Cordeiro, and P. J. Thornalley. 2002. Assay of advanced glycation endproducts (AGEs): surveying AGEs by chromatographic assay with derivatization by 6-aminoquinolyl-Nhydroxysuccinimidyl-carbamate and application to Ne-carboxymethyl-lysine-and Ne-(1-carboxyethyl) lysine-modified albumin. Biochem. J. 364:1-14.
3. Bauer, P. M., J. Yu, Y. Chen, R. Hickey, P. N. Bernatchez, R. Looft-Wilson, et al. 2005. Endothelial-specific expression of caveolin-1 impairs microvascular permeability and angiogenesis. Proc. Natl Acad. Sci. USA 102:204-209.
4. Beltramo, E., F. Pomero, A. Allione, F. D’Alu, E. Ponte, and M. Porta. 2002. Pericyte adhesion is impaired on extracellular matrix produced by endothelial cells in high hexose concentrations. Diabetologia 45:416-419.
5. Berner, A. K., O. Brouwers, R. Pringle, I. Klassen, L. Colhoun, C. McVicar, et al. 2012. Protection against methylglyoxal-derived AGEs by regulation of glyoxalase 1 prevents retinal neuroglial and vasodegenerative pathology. Diabetologia 55:845-854.
6. Bhatwadekar, A. D., J. V. Glenn, G. Li, T. M. Curtis, T. A. Gardiner, and A. W. Stitt. 2008. Advanced glyation of fibronectin impairs vascular repair by endothelial progenitor cells: implications for vasodegeneration in diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 49:1232-1241.
7. Bierhaus, A., T. Fleming, S. Stoyanov, A. Leffler, A. Babes, C. Neacsu, et al. 2012. Methylglyoxal modification of Na(v) 1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat. Med. 18:926-933.
8. Birkenmeier, G., C. Stegemann, R. Hoffmann, R. Günther, K. Huse, and C. Birkemeyer. 2010. Posttranslational modification of human glyoxalase 1 indicates redox-dependent regulation. PLoS ONE 5:e10399.
9. Bornfeldt, K. E., and I. Tabas. 2011. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab. 14:575-585.
10. Brouwers, O., P. M. Niessen, G. Haenen, T. Miyata, M. Brownlee, C. D. Stehouwer, et al. 2010. Hyperglycaemia-induced impairment of endothelium-dependent vasorelaxation in rat mesenteric arteries is mediated by intracellular methylglyoxal levels in a pathway dependent on oxidative stress. Diabetologia 53:989-1000.
11. Brouwers, O., P. M. Niessen, I. Ferreira, T. Miyata, P. G. Scheffer, T. Teerlink, et al. 2011. Overexpression of glyoxalase-I reduces hyperglycemia-induced levels of advanced glycation end products and oxidative stress in diabetic rats. J. Biol. Chem. 286:1374-1380.
12. Brownlee, M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820.
13. Ceradini, D. J., D. Yao, R. H. Grogan, M. Callaghan, D. Edelstein, M. Brownlee, et al. 2008. Decreasing intracellular superoxide corrects defective ischemia-induced new vessel formation in diabetic mice. J. Biol. Chem. 283:10930-10938.
14. Chait, A., and K. E. Bornfeldt. 2009. Diabetes and atherosclerosis: is there a role for hyperglycemia? J. Lipid Res. 50:S335-S339.
15. D’Agord Schaan, B., S. Lacchini, M. C. Bertoluci, M. C. Irigoyen, U. F. Machado, and H. Schmid. 2001. Increased renal GLUT1 abundance and urinary TGF-^a1 in streptozotocin-induced diabetic rats: implications for the development of nephropathy complicating diabetes. Horm. Metab. Res. 33:669.
16. Daugherty, A., and S. C. Whitman. 2003. Quantification of atherosclerosis in mice. Methods Mol. Biol. 209:203-309.
17. Deng, Y. L., and P. H. Yu. 2004. Assessment of the deamination of aminoacetone, an endogenous substrate for semicarbazide-sensitive amine oxidase. Anal. Biochem. 270:97-102.
18. Dobler, D., N. Ahmed, L. Song, K. E. Eboigbodin, and P. J. Thornalley. 2006. Increased dicarbonyl metabolism in endothelial cells in hyperglycemia induces anoikis and impairs angiogenesis by RGD and GFOGER motif modification. Diabetes 55:1961-1969.
19. Dominguez, J. H., K. Camp, L. Maianu, H. Feister, and W. T. Garvey. 1994. Molecular adaptations of GLUT1 and GLUT2 in renal proximal tubules of diabetic rats. Am. J. Physiol. 266:F290.
20. El-Osta, A., D. Brasacchio, D. Yao, A. Pocai, P. L. Jones, R. G. Roeder, et al. 2008. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J. Exp. Med. 205:2409-2417.
21. Forbes, J. M., V. Thallas, M. C. Thomas, H. W. Founds, W. C. Burns, G. Jerums, et al. 2003. The breakdown of pre-existing advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J. 17:NIL272-NIL295.
22. Forbes, J. M., L. T. Yee, V. Thallas, M. Lassila, R. Candido, K. A. Jandeleit-Dahm, et al. 2004. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 53:1813-1823.
23. Fu, M. X., J. R. Requena, A. J. Jenkins, T. J. Lyons, J. W. Baynes, and S. R. Thorpe. 1996. The advanced glycation end product, Ne-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J. Biol. Chem. 271:9982-9986.
24. Genuth, S., W. Sun, P. Cleary, D. R. Sell, W. Dahms, J. Malone, et al. 2005. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 54:3103-3111.
25. Giacco, F., X. Du, V. D. D’Agati, R. Milne, G. Sui, M. Geoffrion, et al. 2014. Knockdown of Glo1 mimics diabetic nephropathy in non-diabetic mice. Diabetes 63:291-299.
26. Goldin, A., J. A. Beckman, A. M. Schmidt, and M. A. Creager. 2006. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114:597-605.
27. Guy, J., L. Ogden, R. P. Wadwa, R. F. Hamman, E. J. Mayer-Davis, A. D. Liese, et al. 2009. Lipid and lipoprotein profiles in youth with and without type 1 diabetes. Diabetes Care 32:416-420.
28. Hammes, H. P., A. Alt, T. Niwa, J. T. Clausen, R. G. Bretzel, M. Brownlee, et al. 1999. Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabetologia 42:728-736.
29. Hanssen, N. M., K. Wouters, M. S. Huijberts, M. J. Gijbels, J. C. Sluimer, L. J. M. Scheijen, et al. 2014. Higher levels of advanced glycation endproducts in human carotid atherosclerotic plaques are associated with a rupture-prone phenotype. Eur. Heart J. 35:1137-1146.
30. Harats, D., H. Kurihara, P. Belloni, H. Oakley, A. Ziober, D. Ackley, et al. 1995. Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter. J. Clin. Invest. 95:1335-1344.
31. Heizmann, C. W. 2007. The mechanism by which dietary AGEs are a risk to human health is via their interaction with RAGE: arguing against the motion. Mol. Nutr. Food Res. 51:1116-1119.
32. Hsueh, W., E. D. Abel, J. L. Breslow, N. Maeda, R. C. Davis, E. A. Fisher, et al. 2007. Recipes for creating animal models of diabetic cardiovascular disease. Circ. Res. 100:1415-1427.
33. Ikeda, Y., R. Inagi, T. Miyata, R. Nagai, M. Arai, M. Miyashita, et al. 2012. Glyoxalase 1 retards renal senescence. Am. J. Pathol. 179:2810-2821.
34. Jandeleit-Dahm, K., and M. E. Cooper. 2008. The role of AGEs in cardiovascular disease. Curr. Pharm. Des. 14:979-986.
35. Januszewski, A. S., N. L. Alderson, S. R. Thorpe, and J. W. Baynes. 2003. Role of lipids in chemical modification of proteins and development of complications in diabetes. Biochem. Soc. Trans. 31:1413-1416.
36. Kalapos, M. P. 2013. Where does plasma methylglyoxal originate from? Diabetes Res. Clin. Pract. 99:260-271.
37. Kanter, J. E., F. Johansson, R. C. LeBoeuf, and K. E. Bornfeldt. 2007. Do glucose and lipids exert independent effects on atherosclerotic lesion initiation or progression to advanced plaques? Circ. Res. 100:769-781.
38. Karachalias, N., R. Babaei-Jadidi, N. Rabbani, and P. J. Thornalley. 2010. Increased protein damage in renal glomeruli, retina, nerve, plasma and urine and its prevention by thiamine and benfotiamine therapy in a rat model of diabetes. Diabetologia 53:1506-1516.
39. Kilhovd, B. K., I. Giardino, P. A. Torjesen, K. I. Birkeland, T. J. Berg, P. J. Thornalley, et al. 2003. Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metabolism 52:163-167.
40. Kurz, A., N. Rabbani, M. Walter, M. Bonin, P. Thornalley, G. Auburger, et al. 2011. Alpha-synuclein deficiency leads to increased glyoxalase I expression and glycation stress. Cell. Mol. Life Sci. 68:721-733.
41. Lassila, M., K. K. Seah, T. J. Allen, V. Thallas, M. C. Thomas, R. Candido, et al. 2004. Accelerated nephropathy in diabetic apolipoprotein E-knockout mouse: role of advanced glycation end products. J. Am. Soc. Nephrol. 15:2125-2138.
42. Meerwaldt, R., H. L. Lutgers, T. P. Links, R. Graaff, J. W. Baynes, R. O. B. Gans, et al. 2007. Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 30:107-112.
43. Miller, A. G., G. Tan, K. J. Binger, R. J. Pickering, M. C. Thomas, R. H. Nagaraj, et al. 2010. Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I function. Diabetes 59:3208-3215.
44. Monnier, V. M. 2003. Intervention against the Maillard reaction in vivo. Arch. Biochem. Biophys. 419:1-15.
45. Myint, K. M., Y. Yamamoto, T. Doi, I. Kato, A. Harashima, H. Yonekura, et al. 2006. RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes 55:2510-2522.
46. Nathan, D. M., P. A. Cleary, J. Y. Backlund, S. Genuth, J. M. Lachin, T. J. Orchard, et al. 2005. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 353:2643-2653.
47. Ohashi, Y., S. Kawashima, K. Hirata, T. Yamashita, T. Ishida, N. Inoue, et al. 1998. Hypotension and reduced nitric oxide-elicited vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase. J. Clin. Invest. 102:2061-2071.
48. Orasanu, G., and J. Plutzky. 2009. The pathological continuum of diabetic vascular disease. J. Am. Coll. Cardiol. 53:S35-S42.
49. Oray, B., and S. J. Norton. 1982. Glyoxalase I from mouse liver. Methods Enzymol. 90:542-546.
50. Paget, C., M. Lecomte, D. Ruggiero, N. Wiernsperger, and M. Lagarde. 1998. Modification of enzymatic antioxidants in retinal microvascular cells by glucose or advanced glycation end products. Free Radic. Biol. Med. 25:121-129.
51. Park, L., K. G. Raman, K. J. Lee, L. J. Ferran, W. S. Chow, D. Stern, et al. 1998. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med. 4:1025-1031.
52. Petitti, D. B., G. Imperatore, S. L. Palla, S. R. Daniels, L. M. Dolan, A. K. Kershnar, et al. 2007. Serum lipids and glucose control. The SEARCH for Diabetes in Youth Study. Arch. Pediatr. Adolesc. Med. 161:159-165.
53. Queisser, M. A., D. Yao, S. Geisler, H. P. Hammes, G. Lochnit, E. D. Schleicher, et al. 2010. Hyperglycemia impairs proteasome function by methylglyoxal. Diabetes 59:670-678.
54. Rabbani, N., and P. Thornalley. 2008. Dicarbonyls linked to damage in the powerhouse: glycation of mitochondrial proteins and oxidative stress. Biochem. Soc. Trans. 36:1045-1050.
55. Rabbani, N., and P. J. Thornalley. 2012. Dicarbonyls (Glyoxal, methylglyoxal, and 3-deoxyglucosone). Pp. 177-192 in T. Niwa, ed. Uremic toxins. Wiley-Blackwell, Hoboken, NJ.
56. Rabbani, N., L. Godfrey, M. Xue, F. Shaheen, M. Geoffrion, R. Milne, et al. 2011. Glycation of LDL by methylglyoxal increases arterial atherogenicity. A possible contributor to increased risk of cardiovascular diabetes. Diabetes 60:1973-1980.
57. Ramasamy, R., and I. J. Goldberg. 2010. Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model. Circ. Res. 106:1149-1158.
58. Ramasamy, R., S. F. Yan, and A. M. Schmidt. 2007. Arguing for the motion: yes, RAGE is a receptor for advanced glycation endproducts. Mol. Nutr. Food Res. 51:1111-1115.
59. Reiniger, N., K. Lau, D. McCalla, B. Eby, B. Cheng, Y. Lu, et al. 2010. Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse. Diabetes 59:2043-2054.
60. Renard, C., and E. Van Obberghen. 2006. Role of diabetes in atherosclerotic pathogenesis. What have we learned from animal models? Diabetes Metab. 32:15-29.
61. Renard, C. B., F. Kramer, F. Johansson, N. Lamharzi, L. R. Tannock, M. G. von Herrath, et al. 2006. Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J. Clin. Invest. 114:659-668.
62. Schaan, B. D., M. C. Irigoyen, M. C. Bertoluci, N. G. Lima, J. Passaglia, E. Hermes, et al. 2005. Increased urinary TGF-â1 and cortical renal GLUT1 and GLUT2 levels: additive effects of hypertension and diabetes. Nephron Physiol. 100:50.
63. Singh, R., A. Barden, T. Mori, and L. Beilin. 2001. Advanced glycation end-products: a review. Diabetologia 44:129-146.
64. Soro-Paavonen, A., A. M. D. Watson, J. Li, K. Paavonen, A. Koitka, A. C. Calkin, et al. 2008. RAGE deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 57:2461-2469.
65. Sugimoto, K., Y. Nishizawa, S. Horiuchi, and S. Yagihashi. 1997. Localization in human diabetic peripheral nerve of Ne-carboxylmethyllysine-protein adducts, an advanced glycation endproduct. Diabetologia 40:1380-1387.
66. Takahashi, M., Y. Lu, T. Myint, J. Fujii, Y. Wada, and N. Taniguchi. 1995. In vivo glycation of aldehyde reductase, a major 3-deoxyglucosone reducing enzyme: identification of glycation sites. Biochemistry 34:1433-1438.
67. Thangarajah, H., D. Yao, E. Chang, Y. Shi, L. Jazayeri, I. N. Vial, et al. 2009. The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc. Natl Acad. Sci. USA 106:13505-13510.
68. The DCCT Research Group. 1992. Lipid and lipoprotein levels in patients with IDDM. Diabetes Control and Complication trial experience. Diabetes Care 15:886-894.
69. The Diabetes Control and Complications Trial Research Group. 1993. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329:977-986.
70. The Diabetes Control and Complications Trial Research Group. 1995. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am. J. Cardiol. 75:894-903.
71. Thornalley, P. J. 1993. The glyoxalase system in health and disease. Mol. Aspects Med. 14:287-371.
72. Thornalley, P. J. 1998. Glutathione-dependent detoxification of a-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. Chem. Biol. Interact. 111-112:137-151.
73. Thornalley, P. J. 2003. Glyoxalase I-structure, function and a critical role in the enzymatic defence against glycation. Biochem. Soc. Trans. 31:1343-1348.
74. Thornalley, P. J., S. Battah, N. Ahmed, N. Karachalias, S. Agalou, R. Babaei-Jadidi, et al. 2003. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem. J. 375:581-592.
75. Tilton, R. G., K. Chang, K. S. Hasan, S. R. Smith, J. M. Petrash, T. P. Misko, et al. 2009. Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 42:221-232.
76. Toth, C., L. L. Rong, C. Yang, J. Martinez, F. Song, N. Ramji, et al. 2008. RAGE and experimental diabetic neuropathy. Diabetes 57:1002-1017.
77. Turk, Z. 2010. Glycotoxins, carbonyl stress and relevance to diabetes and its complications. Physiol. Res. 59:147-156.
78. Ulrich, P., and A. Cerami. 2001. Protein glycation, diabetes and aging. Recent Prog. Horm. Res. 56:1-21.
79. Vasan, S., P. Foiles, and H. Founds. 2003. Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Arch. Biochem. Biophys. 419:89-96.
80. Vlassara, H., and M. R. Palace. 2002. Diabetes and advanced glycation endproducts. J. Inter. Med. 251:87-101.
81. Vulesevic, B., B. McNeill, M. Geoffrion, D. Kuraitis, J. E. McBain, M. Lochhead, et al. 2014. Glyoxalase-1 over-expression in bone marrow cells reverses defective neovascularization in STZ-induced diabetic mice. Cardiovasc. Res. 101:306-316.
82. Wang, H., J. Liu, and L. Wu. 2009. Methylglyoxal-induced mitochondrial dysfunction in vascular smooth muscle cells. Biochem. Pharmacol. 77:1709-1716.
83. Watson, A. M. D., A. Soro-Paavonen, K. Sheehy, J. Li, A. C. Calkin, A. Koitka, et al. 2011. Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout mice. Diabetologia 54:681-689.
84. Wolffenbuttel, B. H., C. M. Boulanger, F. R. Crijns, M. S. Huijberts, P. Poitevin, G. N. Swennen, et al. 1998. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc. Natl Acad. Sci. USA 95:4630-4634.
85. Wu, L., and B. H. J. Juurlink. 2002. Increased methylglyoxal and oxidative stress in hypertensive rat vascular smooth muscle cells. Hypertension 39:809-814.
86. Xue, M., Q. Quan, A. Adaikalakoteswari, N. Rabbani, B. J. Roya, and P. Thornalley. 2008. Activation of NF-E2-related factor-2 reverses biochemical dysfunction of endothelial cells induced by hyperglycemia linked to vascular disease. Diabetes 57:2809-2817.
87. Yan, S. F., R. Ramasamy, Y. Naka, and A. M. Schmidt. 2003. Glycation, inflammation, and RAGE. A scaffold for the macrovascular complications of diabetes and beyond. Circ. Res. 93:1159-1169.
88. Yao, D., and M. Brownlee. 2009. Hyperglycemia-induced reactive oxygen species increase expression of RAGE and RAGE ligands. Diabetes 59:249-255.
89. Yao, D., T. Taguchi, T. Matsumura, R. Pestell, D. Edelstein, I. Giardino, et al. 2007. High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A. J. Biol. Chem. 282:31038-31045.
90. Zheng, H., S. A. Whitman, W. Wu, G. T. Wondrak, P. K. Wong, D. Fang, et al. 2011. Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes 60:3055-3066.